|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ODR4 |
Gene summary for ODR4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ODR4 | Gene ID | 54953 |
| Gene name | odr-4 GPCR localization factor homolog | |
| Gene Alias | C1orf27 | |
| Cytomap | 1q31.1 | |
| Gene Type | protein-coding | GO ID | GO:0008104 | UniProtAcc | Q5SWX8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54953 | ODR4 | LZE2T | Human | Esophagus | ESCC | 2.18e-04 | 6.95e-01 | 0.082 |
| 54953 | ODR4 | LZE4T | Human | Esophagus | ESCC | 9.66e-09 | 2.52e-01 | 0.0811 |
| 54953 | ODR4 | LZE5T | Human | Esophagus | ESCC | 1.57e-02 | 2.52e-01 | 0.0514 |
| 54953 | ODR4 | LZE7T | Human | Esophagus | ESCC | 3.01e-10 | 3.83e-01 | 0.0667 |
| 54953 | ODR4 | LZE8T | Human | Esophagus | ESCC | 1.10e-02 | 1.33e-01 | 0.067 |
| 54953 | ODR4 | LZE20T | Human | Esophagus | ESCC | 1.30e-10 | 3.71e-01 | 0.0662 |
| 54953 | ODR4 | LZE22T | Human | Esophagus | ESCC | 6.95e-12 | 5.15e-01 | 0.068 |
| 54953 | ODR4 | LZE24T | Human | Esophagus | ESCC | 2.62e-15 | 3.55e-01 | 0.0596 |
| 54953 | ODR4 | LZE21T | Human | Esophagus | ESCC | 6.52e-03 | 2.77e-01 | 0.0655 |
| 54953 | ODR4 | NAFLD1 | Human | Liver | NAFLD | 2.79e-07 | 5.22e-01 | -0.04 |
| 54953 | ODR4 | S014 | Human | Liver | HCC | 3.93e-09 | 3.47e-01 | 0.2254 |
| 54953 | ODR4 | S015 | Human | Liver | HCC | 4.51e-08 | 3.57e-01 | 0.2375 |
| 54953 | ODR4 | S016 | Human | Liver | HCC | 3.89e-14 | 3.83e-01 | 0.2243 |
| 54953 | ODR4 | S027 | Human | Liver | HCC | 6.05e-08 | 5.69e-01 | 0.2446 |
| 54953 | ODR4 | S028 | Human | Liver | HCC | 8.20e-24 | 7.34e-01 | 0.2503 |
| 54953 | ODR4 | S029 | Human | Liver | HCC | 5.02e-21 | 8.00e-01 | 0.2581 |
| 54953 | ODR4 | RNA-P10T2-P10T2-2 | Human | Lung | AAH | 7.31e-03 | 5.93e-01 | -0.1406 |
| 54953 | ODR4 | RNA-P17T-P17T-2 | Human | Lung | IAC | 1.26e-09 | 7.77e-01 | 0.3371 |
| 54953 | ODR4 | RNA-P17T-P17T-4 | Human | Lung | IAC | 1.48e-03 | 5.86e-01 | 0.343 |
| 54953 | ODR4 | RNA-P17T-P17T-6 | Human | Lung | IAC | 4.28e-05 | 5.78e-01 | 0.3385 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |